ONC-392-001 Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and
in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.

NCT04140526

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and
in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.

Associated Conditions

Multiple Tumor Types

Principal Investigator

Guru Sonpavde

Sponsor

OncoC4, Inc.

This is a research study to find out if an experimental drug called ONC-392 is safe and effective in cancer patients and how the drug is absorbed and processed in the body of patients with cancer. ONC-392 is an antibody drug that regulates the immune system to treat cancer. This type of treatment is called immunotherapy.

This study is currently enrolling.